{"transactions":[{"id":724101,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:36:27.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":5.5,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-26-000301","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000301/form4.xml","form_type":"4"}},{"id":1101099,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-26T20:31:16.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":5860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":5860,"derivative":{"exercise_price":7.63,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":5860},"source":{"system":"sec-edgar","filing":"0001610717-25-000259","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000259/form4.xml","form_type":"4"}},{"id":1467281,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T20:08:13.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":0.38,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001610717-24-000371","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000371/form4.xml","form_type":"4"}},{"id":1612459,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:29:47.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":4411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":4411,"derivative":{"exercise_price":0.96,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":4411},"source":{"system":"sec-edgar","filing":"0001610717-24-000095","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000095/form4.xml","form_type":"4"}},{"id":1612458,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:29:47.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":26.58,"exercise_date":"2022-06-17","expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000095","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000095/form4.xml","form_type":"4"}},{"id":1754336,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Warrant (Right to Buy)","published_at":"2023-10-27T20:15:41.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":3966800,"price":0.125,"value":495850.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":3966800,"derivative":{"exercise_price":0.7568,"exercise_date":"2023-10-25","expiration_date":"2030-10-25","underlying":"Common Stock","underlying_shares":3966800},"source":{"system":"sec-edgar","filing":"0001610717-23-000320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000320/form4.xml","form_type":"4"}},{"id":1754335,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-10-27T20:15:41.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":7933601,"price":0.7568,"value":6004149.2368,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":11025941,"source":{"system":"sec-edgar","filing":"0001610717-23-000320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000320/form4.xml","form_type":"4"}},{"id":1824889,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-21T20:10:20.000Z","date":"2023-07-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":1,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001610717-23-000210","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000210/form4.xml","form_type":"4"}},{"id":2221260,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-27T20:12:37.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.34,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013388","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013388/doc1.xml","form_type":"4"}},{"id":2242397,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-06T20:01:22.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":11918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 2, 2022 (the \"Vesting Start Date\") or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":11918,"derivative":{"exercise_price":6.06,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":11918},"source":{"system":"sec-edgar","filing":"0001104659-22-068500","document":"tm2217670-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922068500/tm2217670-1_4seq1.xml","form_type":"4"}},{"id":2530727,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-01T23:00:56.000Z","date":"2021-10-28","kind":"grant","acquired":true,"shares":23552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 36 equal monthly installments, commencing on October 28, 2021 (the \"Vesting Start Date\"), such that the option shares shall be fully vested on the three-year anniversary of the Vesting Start Date."}],"balance_after":23522,"derivative":{"exercise_price":20,"expiration_date":"2031-10-28","underlying":"Common stock","underlying_shares":23552},"source":{"system":"sec-edgar","filing":"0001104659-21-132480","document":"tm2131250-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921132480/tm2131250-12_4seq1.xml","form_type":"4"}},{"id":2664037,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T21:09:41.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":26.58,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-21-012335","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761921012335/doc1.xml","form_type":"4"}},{"id":3003071,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2020-10-20T20:55:54.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":283550,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":283550},"source":{"system":"sec-edgar","filing":"0001567619-20-018003","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018003/doc1.xml","form_type":"4"}},{"id":3003070,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-10-20T20:55:54.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":662799,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":662799},"source":{"system":"sec-edgar","filing":"0001567619-20-018003","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018003/doc1.xml","form_type":"4"}},{"id":3003069,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T20:55:54.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":2145991,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2145991},"source":{"system":"sec-edgar","filing":"0001567619-20-018003","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018003/doc1.xml","form_type":"4"}},{"id":3003068,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T20:55:54.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":283550,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":3092340,"source":{"system":"sec-edgar","filing":"0001567619-20-018003","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018003/doc1.xml","form_type":"4"}},{"id":3003067,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T20:55:54.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":662799,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":2808790,"source":{"system":"sec-edgar","filing":"0001567619-20-018003","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018003/doc1.xml","form_type":"4"}},{"id":3003066,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-20T20:55:54.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":2145991,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":2145991,"source":{"system":"sec-edgar","filing":"0001567619-20-018003","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018003/doc1.xml","form_type":"4"}},{"id":3101580,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-23T11:07:51.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date."}],"balance_after":12000,"derivative":{"exercise_price":2.4,"expiration_date":"2030-06-21","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001544227-20-000035","document":"wf-form4_159291045464779.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000154422720000035/wf-form4_159291045464779.xml","form_type":"4"}},{"id":3480942,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-21T20:39:35.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to this option will vest on June 20, 2020, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":12000,"derivative":{"exercise_price":11.59,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-038486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919119038486/doc4.xml","form_type":"4"}},{"id":3692594,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":28584,"kind":"person","name":"Nuechterlein Carole","position":1,"cik":"0001665133","reported_name":"Nuechterlein Carole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-17T21:50:11.000Z","date":"2019-01-15","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to this option will vest on January 15, 2020, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":6000,"derivative":{"exercise_price":8.8,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-19-004243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1544227/000120919119004243/doc4.xml","form_type":"4"}}]}